The recent trading activity among Oscar Health's executive leadership draws attention to internal confidence and valuation perceptions within the healthcare sector. Specifically, Richard Scott Blackley, who serves as the Chief Financial Officer of Oscar Health, Inc. (NYSE:OSCR), executed a sale of company stock in May 2026.
On May 18, 2026, Mr. Blackley sold 110,000 shares of the company’s Class A common stock. The sales were executed across a narrow price band, ranging from $25.00 to $25.20 per share. These transactions totaled a value of $2,753,300.
It is important to note that this divestiture was structured under a pre-arranged trading mechanism. The sale proceeded pursuant to a Rule 10b5-1 trading plan, which Mr. Blackley initially adopted on February 12, 2026.
Following the reported transactions, the CFO's direct holdings in Oscar Health Class A common stock amount to 1,106,660 shares. This remaining figure includes shares that are slated for issuance as part of the vesting process for restricted stock units. Furthermore, an additional holding of 75,000 shares is managed indirectly through the MQB Irrevocable Trust.
The timing of this insider sale occurs when Oscar Health shares have been trading near their 52-week high mark of $25.58. This proximity to a peak follows a significant performance period, marked by an 88% surge over the preceding six months. Despite the strong market appreciation and analysis suggesting potential undervaluation, according to InvestingPro's assessment, the stock currently holds a Fair Value estimate of $28.16.
On the operational front, Oscar Health recently released its first quarter 2026 earnings report. The company achieved an earnings per share (EPS) figure of $2.07. This result represents a substantial outperformance against the forecasted expectation of $1.06, effectively doubling what analysts had projected.
However, this strong performance in profitability was offset by concerns regarding top-line growth. During the same quarter, Oscar Health reported a shortfall in revenue. Despite the robust earnings metrics, the revenue figures suggest areas that may require improvement and attention from management.
Looking at broader financial forecasts, analysts project a significant turnaround for the company's profitability this year. While the company has remained unprofitable over the last twelve months, projections anticipate earnings of $1.20 per share. This represents a notable recovery compared to the recent loss figure of $0.15 per share.
In terms of corporate development and analyst sentiment, the source material confirms that there have been no reported mergers or acquisitions for Oscar Health. Additionally, no recent analyst upgrades or downgrades were noted in the latest reports, which contextualizes the current financial activities surrounding the company.
Risks
- Sustaining the current level of profitability while addressing ongoing revenue shortfalls remains a key risk.
- Market expectations are set against a backdrop of past unprofitability, making sustained positive financial performance crucial to maintain investor confidence.
- The lack of reported M&A activity or analyst rating changes suggests that major external catalysts may be absent in the near term.
More from Insider Trading
Risks
- Sustaining the current level of profitability while addressing ongoing revenue shortfalls remains a key risk.
- Market expectations are set against a backdrop of past unprofitability, making sustained positive financial performance crucial to maintain investor confidence.
- The lack of reported M&A activity or analyst rating changes suggests that major external catalysts may be absent in the near term.